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Introduction. A pharmacokinetic (PK) model is proposed for estimation of total and free brain
concentrations of fluvoxamine.
Materials and methods. Rats with arterial and venous cannulas and a microdialysis probe in the frontal
cortex received intravenous infusions of 1, 3.7 or 7.3 mg.kg
j1 of fluvoxamine.
Analysis. With increasing dose a disproportional increase in brain concentrations was observed. The
kinetics of brain distribution was estimated by simultaneous analysis of plasma, free brain ECF and total
brain tissue concentrations. The PK model consists of three compartments for fluvoxamine
concentrations in plasma in combination with a catenary two compartment model for distribution into
the brain. In this catenary model, the mass exchange between a shallow perfusion-limited and a deep
brain compartment is described by a passive diffusion term and a saturable active efflux term.
Results. The model resulted in precise estimates of the parameters describing passive influx into (kin)o f
0.16 min
j1 and efflux from the shallow brain compartment (kout) of 0.019 min
j1 and the fluvoxamine
concentration at which 50% of the maximum active efflux (C50) is reached of 710 ng.ml
j1. The proposed
brain distribution model constitutes a basis for precise characterization of the PK–PD correlation of
fluvoxamine by taking into account the non-linearity in brain distribution.
KEY WORDS: blood-brain barrier; intracerebral microdialysis; PK–PD correlation; selective serotonin
re-uptake inhibitor; transporter.
INTRODUCTION
Selective Serotonin Reuptake Inhibitors (SSRIs) are
the first-line treatment for depression (1,2). SSRIs selec-
tively and powerfully block the serotonin transporter
(SERT) and thereby the reuptake of serotonin (5-HT) in
the presynaptic nerve terminal yielding increased extracel-
lular 5-HT levels and enhancement of serotonergic neuro-
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ABBREVIATIONS: 5-HT, 5-hydroxytryptamine; A50, fluvoxamine
amount in deep brain compartment at which 50% of saturation of the
active removal flux is reached; ADB, amount of fluvoxamine in deep
brain compartment; AP, Anterior-Posterior; ASP, amount of
fluvoxamine in shallow perfusion-limited compartment; AT, total
amount of fluvoxamine in the brain; BBB, blood-brain barrier; BSA,
Bovine Serum Albumin; C50, fluvoxamine concentration in deep
brain compartment at which 50% of saturation of the active removal
flux is reached; CB, total fluvoxamine concentration in the brain.;
CDB, fluvoxamine concentration in deep brain compartment;
Cin, fluvoxamine concentration entering the brain; Cin-rec,
fluvoxamine concentration entering microdialysis probe; CL,
systemic clearance; Cout, fluvoxamine concentration leaving the
brain; Cout-rec, fluvoxamine concentration leaving microdialysis
probe; Cp, fluvoxamine plasma concentration; CSF, cerebrospinal
fluid; CSP, fluvoxamine concentration in shallow perfusion-limited
compartment; CT, total fluvoxamine concentration in the brain; C.V.,
Coefficient of Variation; DMSO, dimethylsulfoxide; ECF,
extracellular fluid; fDB, partition coefficient for deep brain
compartment; fSP, partition coefficient for shallow perfusion-limited
compartment; IIV, inter-individual variability; kdiff, diffusion rate
constant; kin, influx rate constant in the brain; kout, efflux rate
constantfromthebrain; L, Lateral; LC-MS/MS, liquid chromatography-
mass spectrometry/mass spectrometry; MRP, Multidrug Resistance
Protein; MVOF, Minimum Value of Objective Function; NaOH,
sodium hydroxide; Nmax, maximal active removal flux; NONMEM,
nonlinear mixed effects modeling; NSP-DB, net mass exchange between
shallow perfusion-limited compartment and deep brain compartment;
P, partition coefficient; PD, pharmacodynamics; Pgp, P-glycoprotein;
PK, pharmacokinetics; PVP, polyvinylpyrrolidone; Q2, Q3, inter-
compartmental clearances; QB, effective plasma perfusion rate;
Recoveryin vivo, in vivo recovery; S.E., Standard Error; SERT,
serotonin transporter; SSRI, Selective Serotonin Re-uptake Inhibitor;
V,V e r t i c a l ;V1, central volume of distribution; V2, V3, peripheral
volumes of distribution; VT, brain volume; VDB, volume in deep brain
compartment; VSP, volume in shallow perfusion-limited compartment.transmission (3,4). Despite their widespread use and numer-
ous pre-clinical and clinical investigations, very few studies
have addressed the pharmacokinetic–pharmacodynamic (PK–
PD) correlations of SSRIs. This is remarkable since the PK–
PD correlations of SSRIs appear to be rather complex. Upon
chronic treatment important time dependencies in the
pharmacodynamics of SSRIs have been observed (5–7).
In recent years, important progress has been made in the
field of mechanism-based PK–PD modeling. The objective of
mechanism-based PK–PD modeling is to understand, in a
strictly quantitative manner, the mechanisms which deter-
mine the time-course of the intensity of the drug effect in
vivo. A pertinent feature of mechanism-based PK–PD
models is that they contain specific expressions to describe
processes on the causal path between drug administration
and response. This includes the target site distribution, the
target site binding, the target site activation and the
homeostatic feedback mechanisms (8–12).
Modeling of target site distribution kinetics is particularly
important for drugs which act in tissues that are protected by
specific barriers such as the central nervous system (8,9). In
recent years important progress has been made in elucidating
the functionality of the blood-brain barrier and the mecha-
nisms of drug transport to the brain It has been demonstrated
that the distribution of drugs into the brain is restricted for
hydrophilic drugs and for compounds which are substrates for
efflux transporters at the blood-brain barrier (13). Over the
years also various pharmacokinetic brain distribution models
have been proposed (14), which in theory constitute a scientific
basis for the description of target site distribution kinetics in
mechanism-based PK–PD modeling. To date however, non-
linearity in brain distribution has not been taken into account.
The present investigation focuses on the pharmacoki-
netic modeling of the brain distribution of fluvoxamine.
Recently, evidence has been obtained that fluvoxamine may
be a substrate for active efflux transporters at the blood-brain
barrier. Specifically, it has been shown that fluvoxamine
inhibits Pgp in MDR1 cells (a model for human Pgp) as well
as in primary porcine brain capillary endothelial cells (model
for the blood-brain barrier) (15). On the other hand, no
significant Pgp mediated fluvoxamine efflux in MDR-1 cells
was observed in another investigation (16).
The objective of the present investigation was to charac-
terize in a strictly quantitative manner the kinetics of the brain
distribution of fluvoxamine in rats in vivo, including any
pertinent non-linearities To this end, the time-course of the
fluvoxamine concentration in plasma, brain microdialysate
and brain tissue was determined following intravenous admin-
istration of pharmacologically relevant doses of 1, 3.7 or 7.3
mg/kg. On the basis of these results a PK model is proposed
which enables precise estimation of the time course of both
the total and the free fluvoxamine concentration in the brain.
PHARMACOKINETIC MODEL FOR FLUVOXAMINE
BRAIN DISTRIBUTION
The proposed model for the brain distribution kinetics of
fluvoxamine is an extension of a model proposed earlier for
the brain distribution of thiopental (14,17) and is illustrated in
Fig. 1. The brain distribution model consists of three compart-
ments to describe the concentration versus time profile in
plasma in combination with a catenary two compartment
model to describe the distribution of fluvoxamine into the
brain. Within the catenary model, the first brain compart-
ment is a shallow compartment that is in direct contact with
the blood flow and where the concentration is determined by
perfusion (shallow perfusion-limited compartment). The
second compartment is a deep brain compartment in which
the concentration is equal to the measured ECF concen-
trations (deep brain compartment). Fluvoxamine is not able
to enter the deep brain compartment directly, but only
indirectly from the shallow perfusion-limited compartment.
The transport between the two brain compartments is by
diffusion and/or active transport (influx and/or efflux)
mediated by P-glycoprotein (Pgp) and/or other transporters.
Therefore, the distribution of fluvoxamine into the brain is
determined by perfusion of the outer shallow brain tissues
(subscript SP) and exchange with the deep brain compart-
ment (subscript DB):
dAsp
dt
¼ QBCin   QBCout þ NSP DB ð1Þ
dADB
dt
¼  NSP DB ð2Þ
in which ASP is the amount of fluvoxamine in the shallow
perfusion-limited compartment, QB is the effective plasma
perfusion rate, Cin is the concentration entering the shallow
perfusion-limited compartment, Cout is the concentration
leaving the shallow perfusion-limited compartment, NSP-DB
is the net mass exchange between the shallow perfusion-
limited compartment and deep brain compartment and ADB
is the amount of fluvoxamine in the deep brain compartment.
The mass exchange of fluvoxamine between the outer
perfusion-limited brain compartment and the deep brain
compartment contains two components, a passive diffusion term
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Fig. 1. Schematic representation of the proposed pharmacokinetic
model for fluvoxamine in brain. The fluvoxamine plasma concentra-
tion versus time profiles were predicted by a previously developed
population PK model and served as input function for fluvoxamine in
the brain. The catenary brain distribution model consists of a shallow
perfusion-limited brain compartment and a deep brain compartment.
The mass exchange of fluvoxamine between these compartments is
composed of a passive diffusion term and an saturable active removal
flux (k10=elimination rate constant from central plasma compart-
ment; kin=rate constant for distribution into the shallow brain
compartment; kout=rate constant for distribution from the shallow
brain compartment; kdiff=diffusion rate constant between the shallow
perfusion-limited and the deep brain compartment; CSP=concentra-
tion in shallow perfusion-limited compartment; CDB=concentration
in deep brain compartment; Nmax=maximal active removal flux;
C50=fluvoxamine concentration in the deep brain compartment at
which 50% of saturation of the active removal flux is reached).
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flux is saturable the following relation for NSP-DB is obtained:
NSP DB ¼  kdiff CSP   CDB ðÞ þ NmaxCDB= C50 þ CDB ðÞ ð 3Þ
in which kdiff is the diffusion rate constant between the shallow
perfusion-limited and deep brain compartment, CSP is the
concentration in the shallow perfusion-limited compartment,
CDB is the concentration in the deep brain compartment, Nmax
is the maximal active removal flux and C50 is the fluvoxamine
concentration in the deep brain compartment at which 50% of
saturation of the active removal flux is reached.
In the model the values of the rate constants for diffusion
from the shallow perfusion-limited brain compartment and the
deep brain compartment and vice versa were assumed to be
identical. Moreover, in the data-analysis the value of the
parameter kdiff rose to high values, allowing further reduc-
tion of the model by elimination of this parameter. Thus
ultimately rapid equilibrium between fluvoxamine concen-
trations in the shallow perfusion-limited and the deep brain
compartment was assumed resulting in the following rela-
tionship between the concentrations in the shallow perfu-
sion-limited compartment and the deep brain compartment:
CSP ¼ CDB þ
Nmax
Kdiff
CDB= C50 þ CDB ðÞ ð 4Þ
The total amount of fluvoxamine in the brain can be described
by the following equation:
dAT
dt
¼
dASP
dt
þ
dADB
dt
¼ QBCin   QBCout ð5Þ
in which AT is the total amount of fluvoxamine in the brain.
The concentration entering the brain (Cin) is assumed to
be equal to the plasma concentration:
Cin ¼ CP ð6Þ
in which Cp is the plasma concentration.
The concentration leaving the brain (Cout) is determined
by the partition coefficient (P) between drug in plasma and
the concentration in the shallow perfusion-limited brain area:
Cout ¼ CSP=P ð7Þ
In addition, the following constants can be defined:
kin ¼ QB=VT ð8Þ
kout ¼ QB= VTP ðÞ ð 9Þ
in which kin is the influx rate constant in the brain, VT is the
volume of the brain and kout is the efflux rate constant from
the brain.
The differential equation for total fluvoxamine concen-
tration in the brain can be described by:
dCT
dt
¼ kinCp   koutCSP ð10Þ
in which CT is the total fluvoxamine concentration in the
brain.
The relationships between the concentration in the deep
brain compartment and total brain and the concentration in
the shallow perfusion-limited brain compartment and total
brain are defined by:
CDB ¼ fDBCT ð11Þ
CSP ¼ fSPCT ð12Þ
in which fDB and fSP are partition coefficients for the deep
brain compartment and shallow perfusion-limited compart-
ment, respectively.
The partition coefficient for the deep brain compartment
can be calculated by the following formula:
fDB ¼
 N***maxþCT  C50þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N***max CT þC50
   2þ4CTC50
q
2CT
ð13Þ
in which N***max is a lumped parameter that can be defined by:
N*** max ¼
NmaxVSP
kdiffVDB 
> 0 ð14Þ
with a defined by:
  ¼
VSP
VDB
þ 1
  
> 1 ð15Þ
Furthermore, the partition coefficient for the shallow
perfusion-limited compartment can be calculated by the
following equation:
fSP ¼ 1 þ VDB=VSP 1   fDB ðÞ ð 16Þ
The complete mathematical derivations of the model are
presented in Appendix.
The schematic representation of the proposed PK model
in Fig. 1 shows that at low fluvoxamine plasma concentra-
tions relatively low fluvoxamine concentrations will be
present in the deep brain compartment because of the action
of the active efflux transport at the interface of the shallow
and the deep brain compartment. At higher fluvoxamine
concentrations, this active efflux transport becomes saturated
and therefore relatively higher concentrations of fluvoxamine
are observed in the deep brain compartment.
MATERIALS AND METHODS
Chemicals
Fluvoxamine maleate and clovoxamine fumarate were
kindly provided by Solvay Pharmaceuticals (Weesp, The
Netherlands). Dimethylsulfoxide (DMSO), sodium hydrox-
ide (NaOH) and isoamylalcohol were purchased from Merck
(Darmstadt, Germany). Isopentane, ethanol, acetonitrile and
methanol were obtained from Acros (Geel, Belgium).
Heptanewas purchased from Sigma-Aldrich Laborchemikalien
(Seelze, Germany) and ammonium acetate was obtained from
BakerChemicals(Deventer,TheNetherlands).Milliporewater
was obtained from a Milli-Q system (Millipore SA, Molsheim,
France).
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Male Wistar rats (Charles River Wiga GMBH, Sulzfeld,
Germany) weighing 226–250 g were housed in groups for
6–10 days, under standard environmental conditions (ambi-
ent temperature 21-C, humidity 60%, 12-h light/dark cycle).
The animals had free access to food (laboratory chow, Hope
Farms, Woerden, The Netherlands) and acidified water. For
the microdialysis studies 26 animals were used and for the
brain sampling studies 35 animals were used. After surgery
(i.e. for the implantation of arterial and venous cannulas and,
if applicable, a dummy microdialysis probe), the animals in
the microdialysis studies were housed individually for 1 week
and the animals in the brain sampling studies for 2 days. The
study protocol was approved by the Ethical Committee on
Animal Experimentation of Leiden University.
EXPERIMENTAL PROCEDURES
Microdialysis Studies
Surgical Procedures
Animals were anaesthetized by a subcutaneous injection
of 0.1 ml/100 g Ketanest-S\ ((S)-ketaminebase, Parke-Davis,
Hoofddorp, The Netherlands) and an intramuscular injection
of 0.01 ml/100 g Domitor\ (medetomidine hydrochloride,
Pfizer, Capelle a/d IJssel, The Netherlands). A cannula was
implanted in the right jugular vein (10 cm polyethylene
tubing, Portex Limited, Hythe, United Kingdom; I.D.=0.58,
O.D.=0.96 mm) for fluvoxamine administration and a can-
nula in the left femoral artery (4 cm polyethylene tubing,
Portex Limited; I.D.=0.28, O.D.=0.61 mm heat-sealed to 18
cm polyethylene tubing, I.D.=0.58, O.D.=0.96 mm) for
collection of blood samples. The cannulas were subcutane-
ously tunneled and externalized at the back of the neck. The
venous cannula was filled with saline (0.9%, B. Braun
Melsungen AG, Melsungen, Germany) containing heparin
(20 IU.ml
j1, Pharmacy, Leiden University Medical Center,
Leiden, The Netherlands) and the arterial cannula was filled
with 25% (w/v) polyvinylpyrrolidone (PVP, Brocacef,
Maarssen, The Netherlands) solution in saline (0.9%)
containing heparin (20 IU.ml
j1) to prevent blockade by blood
clotting. After implantation of the cannulas, the animals were
instrumented with a microdialysis guide cannula (CMA/12,
Aurora Borealis Control BV, Schoonebeek, The Netherlands)
within the same surgery. A microdialysis guide cannula with a
dummy probe was implanted in the frontal cortex (AP: 3.2; L:
j3.0; V: j1.5 mm from bregma, in accordance with the atlas of
Paxinos and Watson (18)). Two support screws were placed and
the guide was secured in place using dental cement (Simplex
Rapid liquid and powder, Kemdent Associated Dental
Products, United Kingdom).
Microdialysis
One day before implantation of the microdialysis probe,
the probes (CMA/12, membrane length 3 mm, Aurora
Borealis Control BV) were perfused ex vivo overnight with
artificial cerebrospinal fluid (containing: 145 mM NaCl, 0.6
mM KCl, 1.0 mM MgCl2, 1.2 mM CaCl2, 0.2 mM ascorbic
acid in 2 mM phosphate buffer pH 7.4) (19). The dummy
probe was replaced by the microdialysis probe 1 day before
start of the study. Because fluvoxamine appeared to be
adhesive to the microdialysate tubing and microdialysis
probe, the artificial cerebrospinal fluid additionally contained
0.5% (w/v) Bovine Serum Albumin (BSA, Sigma-Aldrich,
Zwijndrecht, The Netherlands), which completely dissolved
the adhesion problems (data not shown). Flow rate during
the whole experiment was constant at 2 ml.min
j1 and the
outlet tubing was connected to a microdialysate fraction
collector (Univentor 820, Antec Leyden BV, Zoeterwoude,
The Netherlands). After intravenous administration of
fluvoxamine, dialysate concentrations were measured over a
period of 5 h. Sampling intervals were 20 or 30 min yielding a
volume of 40 or 60 ml fluvoxamine dialysate sample in both
microdialysis studies. At the end of the experiments, brains of
the animals were removed and the location of the microdialysis
probe was verified by visual inspection. Microdialysate samples
were collected at a temperature of 4-C in the fraction collector,
and subsequently stored at j20-C until analysis. Dosages and
observed fluvoxamine concentrations areexpressed as free base.
In Vivo Recovery
For 20 of the 26 animals used in the microdialysis studies,
individual values for the in vivo recovery were determined by
the method reverse dialysis or retrodialysis by drug after 1 h of
stabilization (20,21). For the remaining six animals, the mean
in vivo recovery value was used to determine true unbound
fluvoxamine concentrations in ECF from dialysate concen-
trations. To exclude any non-linearity in the in vivo recovery,
in the retrodialysis experiments, a range of fluvoxamine
concentrations (6, 12, 30 and 60 ng.ml
j1) in artificial
cerebrospinal fluid containing 0.5% BSA were locally infused
in the frontal cortex. Six dialysate fractions of 20 min were
collected, of which the median four fractions were used for
determination of the in vivo recovery value. This in vivo
recovery was calculated per probe by the loss of fluvoxamine
from the fluvoxamine retrodialysis solution to the surrounding
tissue according to the following equation:
Recoveryinvivo ¼
Cin rec   Cout rec ðÞ
Cin rec
ð17Þ
in which Cin-rec is the fluvoxamine concentration entering the
probe and Cout-rec is the fluvoxamine concentration leaving the
probe. At the end of the retrodialysis phase, the probes were
perfused for 2 h with artificial cerebrospinal fluid containing
0.5% BSA after which no fluvoxamine was detected in
dialysate samples and the administration of fluvoxamine in
the jugular vein could be started.
Dosage Regimen
From the 26 animals used in the microdialysis studies,
8 animals received 1 mg.kg
j1, 8 animals received 3.7 mg.kg
j1
and 10 animals received 7.3 mg.kg
j1 fluvoxamine via a
30-min intravenous infusion in the jugular vein cannula at a
flow rate of 20 ml.min
j1 using a BAS BeeHive pump
(Bioanalytical Systems, West Lafayette, USA).
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A number of 13 arterial blood samples (100 ml) were
collected at variable fixed time intervals from the cannula in
the femoral artery over a time period between 0 and 5 h after
fluvoxamine administration. After collection of each blood
sample, an equal volume of heparinized 0.9% NaCl (20
IU.ml
j1) was administered to the animal. Blood samples
were collected in heparinized eppendorf tubes and kept on
ice during the experiment. After centrifugation (10 min,
5,000 g), 50 ml plasma was transferred into a glass tube and
stored at j20-C until sample analysis.
Brain Sampling Studies
Surgical Procedures
Animals in the brain sampling studies were implanted
with a cannula in the right jugular vein for fluvoxamine
administration and a cannula in the left femoral artery for
collection of blood samples as described for the animals in
the microdialysis studies.
Dosage Regimen
From the 35 animals used in the brain sampling studies,
19 animals received 1 mg.kg
j1 and 16 animals received 7.3
mg.kg
j1 fluvoxamine via the 30-min intravenous infusion in
the jugular vein cannula as described for the microdialysis
studies.
Blood Sampling
A number between 2 and 15 arterial blood samples (100
ml) were collected from the animals between 2.5 and 600 min
from the cannula in the femoral artery after fluvoxamine
administration, dependent on the time of brain sampling.
Blood samples were collected, handled and stored as
described for the microdialysis studies.
Brain Collection
From the 19 animals that received 1 mg.kg
j1 fluvoxamine,
the brains were collected at 10, 20, 30, 45, 75, 90, 105, 120,
135, 150, 180, 210, 240, 270, 300, 330, 360, 390 and 420 min
after fluvoxamine administration. From the 16 animals that
received 7.3 mg.kg
j1 fluvoxamine, the brains were collected
at 15, 30, 45, 60, 75, 90, 105, 120, 135, 200, 250, 550, 600, 650,
700 and 750 min after fluvoxamine administration. The
animals were sacrificed by decapitation after which the
brains were quickly isolated. The brains were frozen in dry
ice-cooled isopentane that was surrounded with cold
ethanol and stored at j20-C until analysis of fluvoxamine
brain levels.
Drug Analysis
Fluvoxamine samples in the microdialysis studies and
brain sampling studies were analyzed for fluvoxamine using
liquid chromatography with tandem mass spectrometry
(LC–MS/MS) as has been described earlier for fluvoxamine
plasma (22) and for fluvoxamine in ECF and brain.
Calibration standards and independent quality control sam-
ples were prepared by addition of fluvoxamine solutions in
DMSO to control plasma, artificial cerebrospinal fluid or
brain. Briefly, in plasma samples, proteins were precipitated
by addition of acetonitrile and a volume of 20 mlo f
supernatant was injected into the system. For the ECF
samples, a volume of 50 ml of the calibration standards or
QC samples in DMSO were added to 50 ml artificial
cerebrospinal fluid. For the ECF samples from the rats, a
volume of 50 mlD M S O ,5 0 0mlH 2Oa n d5 0ml of 500 ng/ml
clovoxamine in DMSO were added. Addition of 100 mlN a O H
increased the pH value to approximately 12. A volume of 4 ml
of heptane-isoamylalcohol (95:5, v/v) was added, the solution
was centrifuged (10 min, 3000 g) and the organic layer was
evaporated to dryness under nitrogen at 65-C. The residues
were dissolved in a mixture of 10 mM ammonium acetate
and acetonitrile (50:50, v/v) and a volume of 30 mlw a s
injected into the system. Control brains and brains from
fluvoxamine treated rats were weighed and nine volumes of
H2O were added before homogenization. A volume of 100
ml of the calibration standards or QC samples in DMSO
were added to 1 ml control brain homogenate. For the brain
samples of the rats, a volume of 100 ml DMSO and 100 mlo f
500 ng/ml clovoxamine in DMSO were added to 1 ml of
brain homogenate. A volume of 2 ml of methanol was
added for extraction and the samples were rotated for 15
min and centrifuged (10 min, 5,000 g). The solutions were
transferred in eppendorf tubes, centrifuged for another time
(10 min, 9,727 g) and a volume of 20 ml was injected into
the system. All fluvoxamine samples were quantified on a
reversed phase LC column (BDS Hypersil C18, 3 mm
particle size, 100 4.6 mm I.D.; Thermo Hypersil-Keystone,
Brussels, Belgium). LC–MS/MS analysis was performed on an
API-4000 MS/MS (Applied Biosystems, Toronto, Canada),
coupled to an HPLC system (Agilent, Palo Alto, USA). The
MS/MS operated in the positive ion mode using the TurboIon-
Spray-interface (electrospray ionization) was optimized for the
quantification of fluvoxamine. For analysis of brain tissue
samples, an additional guard cartridge (Hypersil ODS 5 mm
10 4.0 mm drop-in cartridge, Thermo Electron Corporation,
Brussels, Belgium) with holder (Uniguard holder, Thermo
Electron Corporation)was used.The intra-batch accuracyfrom
independent QC samples was between 80 and 120% over the
entire range of the samples. The limit of quantification for
fluvoxamine was 1 ng.ml
j1 in plasma, brain ECF and brain
tissue.
Data Analysis
A nonlinear mixed effects modeling approach was used
to describe the concentration-time profiles of fluvoxamine in
plasma, brain ECF and brain tissue from all individual
animals simultaneously. All fitting procedures were per-
formed on a personal computer (Intel\ Pentium\ 4 proces-
sor) running under Windows XP using the Compaq Visual
FORTRAN standard edition 6.1 (Compaq Computer Coop-
eration, Euston, Texas, USA) with the nonlinear mixed
effects modeling software NONMEM (Version V, Level
1.1., NONMEM project group, University of California, San
Francisco, USA).
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As described in the development of the fluvoxamine
brain distribution model, the PK information in plasma
obtained in the present study was analyzed in combination
with plasma concentration time data of other studies on the
basis of a previously proposed population three-compartment
PK model for fluvoxamine in plasma (22). The individual
plasma concentration versus time profiles in the animals
included in the present study were estimated on the basis of
the obtained post hoc estimates of the parameters and used
as fluvoxamine input function in the brain. In Table I, the
mean post hoc estimates for the PK parameters of fluvox-
amine inplasmaobtainedby the three-compartment PK model
are depicted. Included are the post hoc estimates for systemic
clearance (CL), central volume of distribution (V1), two
peripheral volumes of distribution (V2, V3) and inter-com-
partmental clearances (Q2, Q3). On the basis of a covariate
analysis, no differences in the pharmacokinetics of the three
different dose groups nor between the rats in the microdialysis
study and the brain sampling study could be detected.
PK Analysis in Brain ECF and Brain Tissue
All fluvoxamine data in plasma, brain ECF and brain
tissue were implemented in the PREDD subroutine
ADVAN 6 TOL5, which is a general nonlinear model that
uses the numerical solution of the differential equations.
Inter-individual variability on the parameters was mod-
eled by an exponential equation:
Pi ¼     exp  i ðÞ ð18Þ
in which Pi is the individual estimate for parameter P for the
ith individual, q is the population estimate for parameter P and
hi is the inter-individual random deviation of Pi from P.T h e
values of hi are assumed to be normally distributed with mean
zero and variance w
2 that distinguished the pharmacokinetic
parameters for the ith individual from the population typical
value q. Inter-individual variabilities were analyzed on each
parameter and the inter-individual effects that did not
significantly improve the model or could not be estimated
were fixed to zero. Correlations between the inter-individual
variabilities of the various parameters were explored using the
OMEGA BLOCK option. Unexplained variability (e.g.
caused by measurement and experimental errors) in
fluvoxamine concentrations in ECF and total brain were best
described by a proportional error:
Cmij ¼ Cij   1 þ eij
  
ð19Þ
in which Cmij is the measured ECF or brain concentration, Cij
is the jth ECF or brain concentration for the ith individual
predicted by the model and (ij account for the residual
deviance of the predicted from the observed concentration.
The values for ( were assumed to be independently normally
distributed with mean zero and variance s
2. Population
pharmacokinetic values of q, w
2 and s
2 were estimated using
the first-order conditional estimation with interaction method
in NONMEM. Model fits were compared on the basis of the
likelihood ratio test (23,24), diagnostic plots, parameter
correlations and precision in parameter estimates. An
additional parameter was included in the structural model if
the resulting change in minimum value of the objective
function (MVOF) was Q6.6 (pe0.01).
RESULTS
In Vivo Recovery of Microdialysis
The average values of the recoveries were 0.20T0.09,
0.36T0.10, 0.27T0.15, 0.25T0.07 for retrodialysis fluvoxamine
solutions of 6, 12, 30 and 60 ng.ml
j1, respectively. Therefore,
a mean recovery value of 0.27T0.10 was used for the six
animals in which no individual values of the in vivo recovery
were obtained.
PK Analysis in Plasma
By application of the previously developed PK model,
individual post hoc estimates for fluvoxamine in plasma
could be obtained for CL, V1, V2, and Q2 (Table I). Inter-
individual variability could not be identified on the param-
eters V3a n dQ3, and therefore the estimates for the
population of 187 animals were used. The individual post
hoc estimates were used in the current studies for each
animal to estimate the fluvoxamine concentrations in plasma
as input function in the brain
Model for Fluvoxamine Brain Distribution
In Fig. 2, observed fluvoxamine concentrations in ECF
(a) and total brain (b) are depicted as well as the upper and
lower limit of interquantile range and the median concentra-
tion versus time for a number of 2,000 datasets that were
simulated from the obtained PK parameter estimates.
Fluvoxamine was transported rapidly into the brain and
maximal ECF and brain concentrations were observed only
about 20 min later than maximal plasma fluvoxamine
concentration. Since maximum concentrations in ECF and
brain were observed at the same time after administration,
Table I. Mean Post Hoc Estimates for the Pharmacokinetic Parameters of Fluvoxamine in Plasma after i.v. Administration in 30 min (1, 3.7
and 7.3 mg.kg
j1) Obtained by the Three-Compartment Pharmacokinetic Model
Study
PK Parameter (unit)
CL (ml.min
j1) V1 (ml) V2 (ml) Q2 (ml.min
j1) V3 (ml) Q3 (ml.min
j1)
Microdialysis+brain sampling 31.6 321 949 33.7 136 1.0
Microdialysis 36.5 412 1,255 39.4 136 1.0
Brain sampling 28.0 253 721 29.4 136 1.0
Depicted are the population mean estimates for CL, V1, V2, Q2, V3, and Q3.
797 Model of Non-linear Fluvoxamine Brain Distributiondistribution between fluvoxamine in ECF and total brain was
very rapid. Furthermore, fluvoxamine concentration-time
curves in ECF and brain showed the same kinetic profiles
without any delay or different elimination kinetics (Fig. 2).
When observed fluvoxamine concentrations were nor-
malized for dose (normalization dose 4 mg.kg
j1), non-
linearity could be observed in ECF and brain, which was
not observed in plasma (Fig. 3). Specifically, with increasing
fluvoxamine dose a disproportional increase in brain ECF
and brain tissue concentrations relative to the plasma
concentrations was observed. Therefore, the proposed PK
model with saturable efflux transport from the deep brain
compartment to the shallow perfusion-limited brain
compartment was compared with a model without such
saturable efflux transport. The proposed PK model with
non-linearity in brain distribution resulted in a significantly
better description of fluvoxamine concentrations in brain
ECF and brain tissue compared with the linear brain model
as reflected in a decrease in MVOF of 37 points.
Fluvoxamine concentrations in ECF and brain could be
adequately described with this model, as shown in Fig. 2.
These Figures also show that the concentration-time curves
of fluvoxamine in ECF and total brain follow the same
kinetic profiles. Therefore, the assumption of the high rate
constants between the compartments in the model was valid
and the concentration-time profiles in ECF and brain were
separated only by a scaling factor.
The structural parameters of the model could be
simultaneously estimated with good precision (Table II).
The influx rate constant in the brain (kin) was 0.16 min
j1 and
the efflux rate from the brain by the shallow perfusion-
limited brain compartment (kout) was 0.019 min
j1.
Fluvoxamine concentration at which 50% of saturation of
t h ea c t i v er e m o v a lf l u xi sr e a c h e d( C50) was equal to 710 ng.ml
j1.
Since measured fluvoxamine ECF concentrations ranged
between 1 and 214 ng.ml
j1, full saturation of the active
removal flux was not reached in the current studies. The
residual error for fluvoxamine concentrations in ECF and
total brain ((1ij) was estimated to be equal to 0.042 and
significantly lower than the estimated value by the model
without incorporated saturation kinetics. Therefore, more
variation could be explained by the model in which
saturation of an active efflux transport was assumed, thus
supporting the validity of the complex model.
The coefficients of variation (C.V.) for the ECF and
brain parameters were lower than 33% for al parameters,
except for C50 and N   max for which the coefficients of
variation were 96.8 and 92.5%, respectively. This can be
explained by the fact that full saturation of the efflux
transporter was not reached in the present investigation.
Inter-individual variability (IIV) for kin was equal to 0.50 and
for kout equal to 0.17. Inter-individual variability in the other
parameters could not be adequately estimated and was fixed
to zero. Correlation between the variability in the estimated
PK parameters was observed for kin and kout and was
implemented in the model. In Fig. 4, goodness-of-fit plots
for fluvoxamine concentrations in ECF of the frontal cortex
and total brain are depicted. Observed ECF concentrations
were in close agreement with individual predicted (a) and
population predicted (b) ECF concentrations. No substantial
or systemic deviation from the identity line was observed
indicating adequate description of observed fluvoxamine
ECF concentrations. Furthermore, no substantial or systemic
deviation from the identity line was present for the observed
fluvoxamine brain concentrations vs. individual (C) and
population (D) predicted brain concentrations. Although
each observation from total brain was collected from a
different animal by destructive sampling, fluvoxamine brain
concentrations could be adequately described.
DISCUSSION
The objective of this investigation was to develop a
pharmacokinetic model for estimation of the time course of
the fluvoxamine brain concentration in rats, to be used in
future PK–PD investigations.
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Fig. 2. Fluvoxamine concentration-time profiles in ECF (a) and total
brain (b), obtained after a 30-min intravenous infusion in Wistar rats.
Depicted are the observed fluvoxamine concentrations (dots), the
model-simulated upper limit of the interquantile concentration range
(90%, upper dashed line), the model simulated lower limit of the
interquantile concentration range (10%, lower dashed line), the
median concentration (solid line) versus time. A number of 2,000
datasets were simulated from the final PK parameter estimates.
798 Geldof, Freijer, van Beijsterveldt and DanhofAn important feature of the present study is that both
the brain ECF concentrations (using microdialysis) as well as
the brain tissue concentrations (by brain tissue sampling)
were measured. By this unique approach, the time course of
both the total and the free fluvoxamine concentration in
brain could be estimated up to 750 min after the administra-
tion of pharmacologically relevant doses (Figs. 2 and 3). The
simultaneous collection of (free) brain ECF and (total) brain
tissue concentrations is conceptually important since, in
theory both total and free drug concentrations can be the
determinant of the pharmacodynamic response (25). More-
over the inclusion of brain concentrations enabled character-
ization of the brain ECF concentrations at the time points
where the concentrations in microdialysate have dropped
below the detection limit.
When fluvoxamine concentrations were normalized for
dose, a small but distinct non-linearity was observed in the
ECF and the brain concentration versus time profiles, but not
in the plasma concentration versus time profiles (Fig. 3). The
non-linearity in brain distribution was further supported by
the results of the covariate analysis. The disproportional
increase in ECF and brain concentrations reflects non-
linearity in the brain distribution. It seems unlikely that this
non-linearity is caused by non-linear plasma protein binding,
since fluvoxamine plasma protein binding in rats is linear
over a wide concentration range. Specifically, in a separate
study with the same experimental set-up and after adminis-
tration of similar dosages, plasma protein binding was found
to be linear with a free fraction of 2.6% (Geldof et al.,
unpublished observations).
In the present study, total rather free drug concentra-
tions in plasma were measured, using serial blood sampling.
In various investigations it has been demonstrated that, when
using appropriate techniques, the collection of serial blood
samples has minimal hemodynamic and CNS effects. An
alternative would be to monitor the time course of (free)
plasma concentrations by intravenous microdialysis. To date
there is limited experience however with this technique in
PK–PD investigations with CNS active drugs. Moreover, a
theoretical disadvantage is that venous drug concentrations
are obtained while the time course of the drug effect is driven
by the arterial concentrations (26).
In the modeling the median time point of the micro-
dialysis sampling interval was used as the observation time
of the concentration. Thereby, the concentration of fluvox-
amine was assumed to decrease in a linear fashion in each
collection interval. This is justified in situations where the
changes in the concentration in each collection interval are
small (27,28).
To overcome the adhesion of fluvoxamine to the micro-
dialysis probe, artificial cerebrospinal fluid contained 0.5%
BSA. It cannot be excluded that this affects the recovery.
However, since BSA was also added in the recovery experi-
ments, such an effect is in principle accounted for in the
recovery. Furthermore, given the low BSA concentration in
microdialysate an eventual effect on the recovery is likely to
be minimal.
For experimental reasons, individual values of the
recovery could not be obtained in 6 of the 27 rats. In these
animals the mean recovery of 0.27 was used. Given the
observed wide inter-animal variability in the recovery, there
is a considerable uncertainty in the value of the recovery in
these animals. Yet, under these circumstances the use of the
mean recovery was considered the most appropriate.
The proposed PK model for description of non-linear
brain distribution of fluvoxamine constitutes an extension of
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Fig. 3. Observed fluvoxamine concentration-time profiles in plasma
(a), ECF (b) and total brain (c), after normalization for dose
(normalization dose 4 mg.kg
j1) separated by fluvoxamine dose.
799 Model of Non-linear Fluvoxamine Brain Distributionan earlier model for the brain distribution of thiopental
(14,17). In this catenary two-compartment brain distribution
model, a shallow perfusion-limited compartment and a
deeper membrane-limited compartment are postulated, in
which the distribution of drug into the deep compartment is
defined by a permeability term. Interestingly, in a recent
study an extended catenary biophase distribution model was
found to best describe the PK–PD correlation for the EEG
effect of morphine (29). The developed PK model for
fluvoxamine brain distribution is an extension of the brain
distribution model for thiopental by the addition of an active
saturable efflux term. In this manner, it was possible to
adequately estimate the time course of the total and free
brain fluvoxamine concentration (Figs. 2 and 4).
In the modeling it was assumed that the values of the
rate constants for diffusion between the shallow and the deep
brain compartment and vice versa are identical. This was
necessary since independent estimation of these rate con-
stants was not feasible. The practice of assuming identical
values of the distribution rate constants is neither unreason-
able nor uncommon (8). When analyzing the data, the value
of the intercompartmental distribution rate constant kdiff rose
to very high values. The parameter kdiff could therefore be
removed from the model without affecting the goodness of fit
and the precision of the parameter estimates.
In the present investigation the brain distribution of
fluvoxamine was studied in the pharmacologically relevant
dose range of 1–7.3 mg.kg
j1. Although a distinct non-
linearity in brain distribution was detected, the precision of
the parameters characterizing this non-linearity was not very
high. Specifically the values for the C.V. for C50 and N   max
were estimated as 96.8 and 92.5% respectively. This can be
explained by the fact that the concentrations at which full
saturation occurs lay well above the actually observed con-
Table II. Population Pharmacokinetic Parameter Estimates of
Fluvoxamine in ECF and Brain after i.v. Administration in 30 min
(1, 3.7 and 7.3 mg.kg
j1) Obtained by the Conceptual PK Model
Parameter Unit Value C.V. (%)
kin min
j1 0.16 13.6
kout min
j1 0.019 8.1
N   max ng.h
j1 30,700 92.5
C50 ng.ml
j1 710 96.8
w
2 hkin – 0.50 25.7
w
2 hkout – 0.17 28.5
wh kin/wh kout – 0.24 32.9
s
2 (1ij – 0.042 17.3
C.V.=coefficient of variation (standard error value * 100%)
Depicted are the population mean estimates for kin, kout, N***max,
C50, w
2, s
2 with corresponding coefficient of variation (C.V.)
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Fig. 4. Goodness-of-fit plotsoffluvoxamine concentrationsinECF andtotal brainobtainedfor the physiological PK model.
Depicted are scatter plots of the observed fluvoxamine ECF concentrations versus the individual model predictions (a)a n d
population model predictions (b) and observed fluvoxamine brain concentrations versus the individual model predictions
(c) and population model predictions (d). The limit of quantification (1 ng.ml
j1) is added for clarity (dashed line).
800 Geldof, Freijer, van Beijsterveldt and Danhofcentrations. Specifically, the value of the C50 (710 ng.ml
j1)
lies well above the observed maximum ECF concentration of
210 ng.ml
j1. Nevertheless, inclusion of a saturable function
was necessary for a precise description of the brain
distribution (Fig. 3). Incorporation of the saturable active
efflux term in the model significantly improved the goodness
of fit as reflected in a decrease of the MVOF by 37 points.
Furthermore, estimates of kin and kout were not influenced by
the value of parameters values for C50 and therefore, were
not dependent on a precise description of the maximal
concentrations by the model at which complete saturation
of the active removal flux was reached. In recent PK–PD
investigation using serotonin reuptake transporter (SERT)
occupancy as a pharmacodynamic endpoint, it was found that
incorporation of non-linear brain distribution of fluvoxamine
results in a significant improvement of the Fgoodness-of-fit_
(Geldof et al., unpublished observations).
In recent years much progress has been made in
elucidating the mechanisms of BBB-transport of drugs. In
particular, the functionality of active efflux pumps like
P-glycoprotein (Pgp) and multidrug resistance protein (MRP)
appears to be an important determinant of brain concentra-
tion(30,31).Thereareindicationsthatfluvoxaminemayindeed
be a substrate for these transporters. Specifically, it was shown
in vitro that fluvoxamine induces intermediate Pgp inhibi-
tion in MDR1 cells (model for human Pgp) as well as in
primary porcine brain capillary endothelial cells (model
f o rt h eB B B )( 15), although this could not be confirmed in
another study in MDR-1 cells (16). However, in this latter
study the in vitro passive permeability of fluvoxamine was
rather high (317 nm.s
j1), thereby possibly obscuring the
contribution of the active efflux. The role of Pgp in the
brain distribution of fluvoxamine could be further explored
on the basis of the interaction with specific Pgp inhibitors in
microdialysis studies, as has recently been demonstrated for
morphine (33).
Next to the model described in this article, an
alternative model in which non-linear brain distribution
was described on the basis of non-linear tissue binding to
the serotonin reuptake transporter (SERT) using the
concept of target-mediated disposition, (34–36) was ex-
plored. Although this model described the observed data
equally well as reflected in an equal value of the goodness-
of-fit parameter, the values of the parameters describing
the non-linear binding in the brain were completely
different from the pertinent parameters describing the
binding of fluvoxamine to SERT (Geldof et al., unpublished
observations). Therefore, the currently proposed model
appears to be the most mechanistically plausible model to
describe the observed non-linearity in the brain distribution
of fluvoxamine.
In conclusion, a PK model was developed that could
adequately describe observed non-linearity in fluvoxamine
brain distribution. Specifically the models enables precise
prediction of the time course of both the free and the total
brain concentration of fluvoxamine following pharmacological-
ly relevant doses of 1, 3.7 and 7.3 mg.kg
j1 via a 30-min
intravenous infusion in the rat. The developed PK model will
be used in future mechanistic investigations on the pharmaco-
kinetic–pharmacodynamic correlations on fluvoxamine in
the rat (37).
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APPENDIX
Derivations of the Proposed Physiological Model
for Fluvoxamine Brain Distribution
Consider the brain to exist of two areas. The first area is
a brain compartment that is in direct contact with the blood
flow in which the mass balance is perfusion limited. This
compartment area is defined as shallow perfusion-limited
compartment (subscript SP). The second brain area is a deep
brain compartment representing measured fluvoxamine con-
centrations in ECF (subscript DB). Fluvoxamine cannot
enter this area by perfusion, but only by diffusion or active
transport that could be mediated by Pgp or other trans-
porters. The shallow perfusion-limited compartment and
deep brain compartment build the total brain. The total
brain concentrations were also measured in the current study.
The differential equation for the mass balance in the
brain is determined by perfusion of the outer shallow
perfusion-limited tissues and exchange with the deep brain
compartment:
dASP
dt
¼ QBCin   QBCout þ NSP DB ð20Þ
dADB
dt
¼  NSP DB ð21Þ
in which ASP is the amount of fluvoxamine in shallow
perfusion-limited compartment, QB is the effective plasma
perfusion rate, Cin is the fluvoxamine concentration entering
the shallow perfusion-limited compartment, Cout is the
fluvoxamine concentration leaving the shallow perfusion-
limited compartment, NSP-DB is the net mass exchange
between the shallow perfusion-limited compartment and
deep brain compartment and ADB is the amount of fluvox-
amine in the deep brain compartment.
The process of mass exchange between the shallow
perfusion-limited compartment and the deep brain compart-
ment is supposed to have two components, a passive diffusive
term and an active removal flux. By assuming that the latter
process is saturable, the following relation can be obtained:
NSP DB ¼  kdiff CSP   CDB ðÞ þ NmaxCDB= C50 þ CDB ðÞ ð 22Þ
in which kdiff is the diffusion rate constant, CSP is the
fluvoxamine concentration in the shallow perfusion-limited
compartment, CDB is the fluvoxamine concentration in the
801 Model of Non-linear Fluvoxamine Brain Distributiondeep brain compartment, Nmax is the maximal active removal
flux and C50 is the fluvoxamine concentration in deep brain
compartment at which 50% of saturation of the active
removal flux is reached. Consequently the following relations
are obtained:
dASP
dt
¼ QBCin   QBCout   kdiff CSP   CDB ðÞ
þ NmaxCDB= C50 þ CDB ðÞ ð 23Þ
dADB
dt
¼ kdiff CSP   CDB ðÞ   NmaxCDB= C50 þ CDB ðÞ ð 24Þ
By assuming that the rate constants are high the following
equations can be obtained:
1
kdiff
dADB
dt
¼ CSP   CDB ðÞ  
Nmax
kdiff
CDB= C50 þ CDB ðÞ ð 25Þ
0 ¼ CSP   CDB ðÞ  
Nmax
kdiff
CDB=C50 þ CDB ð26Þ
CSP ¼ CDB þ
Nmax
kdiff
CDB=C50 þ CDB ð27Þ
or
ASP ¼ ADB
VSP
VDB
þ
NmaxVSP
kdiff
ADB=A50 þ ADB ð28Þ
in which VSP is the volume in shallow perfusion-limited
compartment, VDB is the volume in the deep brain compart-
ment and A50 is the fluvoxamine amount in the deep brain
compartment at which 50% of saturation of the active
removal flux is reached.
The mass balance in the brain can be expressed in terms
of one differential equation:
dAT
dt
¼
dASP
dt
þ
dADB
dt
¼ QBCin   QBCout ð29Þ
in which AT is the total amount of fluvoxamine in the brain.
Assume that the entering concentration is equal to the
plasma concentration:
Cin ¼ Cp ð30Þ
in which Cp is the fluvoxamine concentration in plasma.
The concentration leaving the brain is determined by the
partition coefficient between drug in plasma and the concen-
tration in the shallow perfusion-limited compartment:
Cout ¼ CSP=P ð31Þ
in which P is the partition coefficient. Accordingly:
dAT
dt
¼ QBCp   QBCSP=P ð32Þ
Dividing by brain volume results in the following equation:
dCT
dt
¼ QBCp
 
VT   QBCSP= VTP ðÞ ð 33Þ
in which CT is the total fluvoxamine concentration in the
brain and VT is the total brain volume.
Now, define the following constants:
kin ¼ QB=VT ð34Þ
kout ¼ QB= VTP ðÞ ð 35Þ
in which kin is the influx rate constant in the brain and kout is
the efflux rate constant from the brain.
As a result the following relationship is obtained:
dCT
dt
¼ kinCp   koutCSP ð36Þ
As a consequence we need to know the relationship between:
(1) The concentration in the deep brain compartment
and total brain concentration:
CDB ¼ fDBCT ð37Þ
(2) The concentration in the shallow perfusion-limited
compartment and total brain concentration:
CSP ¼ fSPCT ð38Þ
in which fDB is the partition coefficient for the deep brain
compartment and fSP is the partition coefficient for the
shallow perfusion-limited compartment.
Equation 37 is needed to calculate the concentration in
the deep brain compartment as a function of the total
concentration. Equation 38 is needed for calculating the
concentration in the shallow perfusion-limited compartment
and for calculating the mass balance of the total brain in Eq.
36. Substitution of Eq. 38 in Eq. 36 yields:
dCT
dt
¼ kinCp   koutfSPCT ð39Þ
The relationships in Eqs. 37 and 38 can be found by solving
Eq. 37:
ASP ¼ ADB
VSP
VDB
þ
NmaxVSP
kdiff
ADB= A50 þ ADB ðÞ ð 40Þ
Further the relation of the total amount of fluvoxamine in
the brain is known:
AT ¼ ASP þ ADB ð41Þ
and therefore:
AT   ADB ¼ ADB
VSP
VDB
þ
NmaxVSP
kdiff
ADB= A50 þ ADB ðÞ ð 42Þ
AT ¼ ADB
VSP
VDB
þ 1
  
þ
NmaxVSP
kdiff
ADB= A50 þ ADB ðÞ ð 43Þ
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  ¼
VSP
VDB
þ 1
  
> 1 ð44Þ
N*max ¼
NmaxVSP
kdiff
> 0 ð45Þ
the following relationship for the total fluvoxamine amount
in the brain is obtained:
AT ¼ ADB  þ
N*maxADB
A50 þ ADB
ð46Þ
Rearrangement results in:
 A2
DB þ N*max   AT þ  A50
  
ADB   ATA50 ¼ 0 ð47Þ
For which the solution is equal to:
ADECF ¼
 b þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
b2   4ac
p
2a
ð48Þ
with:
c ¼  ATA50 ð49Þ
b ¼ N*max   AT þ  A50 ð50Þ
a ¼   ð51Þ
The concentration in the deep brain compartment can
be calculated from the total brain concentration by:
CDB
CT
¼
ADB VDB þ VSP ðÞ
ATVDB
ð52Þ
CDB ¼
ADB VDB þ VSP ðÞ
ATVDB
CT ð53Þ
CDB ¼ fDBCT ð54Þ
with the fraction:
fDB ¼
VDB þ VSP ðÞ
VDBAT
 
 b þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
b2   4ac
p
2a
ð55Þ
N***max ¼
NmaxVSP
kdiff 1 þ VDB ðÞ
> 0 ð56Þ
fDB ¼
 N***maxþCT  C50þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N***max CT þC50
   2þ4CTC50
q
2CT
ð57Þ
To calculate the concentration in the shallow perfusion-
limited compartment from the total brain concentration use:
CSP ¼ fSPCT ð38Þ
Recall that:
CDB ¼ fDBCT ð37Þ
ADB=VDB ¼ fDBAT= VDB þ VSP ðÞ ð 58Þ
And therefore the partition coefficient for the shallow
perfusion-limited compartment can be calculated by:
fSP ¼ 1 þ VDB=VSP 1   fDB ðÞ ð 59Þ
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